Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as an intravenous solution for intravenous use. It is used to treat congenital antithrombin deficiency and to prevent thromboembolic events in patients at high risk of thrombosis, such as those undergoing surgery. GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kybernin P is an antithrombin concentrate indicated for conditions affecting the coagulation pathway.

- Congenital antithrombin deficiency: restores antithrombin activity to reduce spontaneous clot formation. - Surgical thrombosis prophylaxis: lowers the risk of peri‑operative thromboembolic events in high‑risk patients. - Cardiopulmonary bypass support: maintains adequate antithrombin levels during extracorporeal circulation to prevent clotting.

Kybernin P may be associated with several adverse reactions following intravenous administration.

Common Side Effects: - Fever or chills: transient temperature elevation after infusion. - Headache: mild to moderate discomfort during or after dosing. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Significant bleeding: excessive hemorrhage due to over‑anticoagulation. - Thrombotic events: paradoxical clot formation in rare cases.

Prior to initiating therapy with Kybernin P, clinicians should consider several safety measures.

- Monitor antithrombin levels: ensure therapeutic concentrations are achieved. - Assess bleeding risk: evaluate patient history for hemorrhagic disorders. - Avoid use in known hypersensitivity: discontinue if allergic reactions occur. - Adjust in renal/hepatic impairment: consider dose modification in organ dysfunction. - Concomitant anticoagulants: review and possibly adjust other anticoagulant therapies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Heparin: combined use may markedly increase bleeding risk. - Direct oral anticoagulants (e.g., rivaroxaban, apixaban): additive anticoagulant effect.

Moderate Interactions (Monitor Closely): - Aspirin or NSAIDs: heightened risk of gastrointestinal bleeding. - Antiplatelet agents (e.g., clopidogrel): monitor for combined antithrombotic effect. - Thrombolytic therapy: increased potential for hemorrhage.